MCID: PLS007
MIFTS: 59

Plasmodium Falciparum Malaria

Categories: Infectious diseases

Aliases & Classifications for Plasmodium Falciparum Malaria

MalaCards integrated aliases for Plasmodium Falciparum Malaria:

Name: Plasmodium Falciparum Malaria 12 14
Malaria, Falciparum 41 69
Plasmodium Falciparum Malaria, Unspecified 12
Falciparum Malaria [malignant Tertian] 12
Malaria Fever, Subtertian 12
Malignant Tertian Fever 12
Falciparum Malaria 12
Malaria Falciparum 51

Classifications:



External Ids:

Disease Ontology 12 DOID:14067
ICD10 32 B50 B50.9 B50.0
ICD9CM 34 084.0
MeSH 41 D016778
NCIt 46 C34798
UMLS 69 C0024535

Summaries for Plasmodium Falciparum Malaria

Disease Ontology : 12 A malaria described as a severe form of the disease caused by a parasite Plasmodium falciparum, which is marked by irrregular recurrence of paroxysms and prolonged or continuous fever.

MalaCards based summary : Plasmodium Falciparum Malaria, also known as malaria, falciparum, is related to schistosomiasis and q fever. An important gene associated with Plasmodium Falciparum Malaria is CR1 (Complement C3b/C4b Receptor 1 (Knops Blood Group)), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Amodiaquine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and skin, and related phenotypes are hematopoietic system and cellular

Related Diseases for Plasmodium Falciparum Malaria

Diseases related to Plasmodium Falciparum Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 236)
# Related Disease Score Top Affiliating Genes
1 schistosomiasis 30.7 IFNG IL10 TNF
2 q fever 30.6 IFNG IL10 TNF
3 sickle cell anemia 30.3 G6PD HBB TNF
4 plasmodium vivax malaria 29.7 G6PD ICAM1 IFNG IL10 SELE TNF
5 glomerulonephritis 29.2 CR1 ICAM1 MIF TLR9
6 asthma 28.8 ICAM1 IFNG IL10 IL18 SELE TLR9
7 dermatitis, atopic 28.6 ICAM1 IFNG IL10 IL18 SELE TLR9
8 malaria 27.3 CD36 CD55 CHIT1 CR1 DHFR FCGR2A
9 anemia, nonspherocytic hemolytic, due to g6pd deficiency 11.3
10 punctate inner choroidopathy 10.6 IL10 TNF
11 tropical endomyocardial fibrosis 10.6 IL10 TNF
12 hyperlucent lung 10.5 IFNG IL10
13 microscopic polyangiitis 10.5 IL10 TNF
14 staphylococcal toxic shock syndrome 10.5 IFNG TNF
15 aging 10.5
16 multifocal choroiditis 10.5 IL10 TNF
17 systemic onset juvenile idiopathic arthritis 10.5 IL18 TNF
18 tungiasis 10.5 IL10 TNF
19 autoimmune myocarditis 10.5 IFNG TNF
20 endomyocardial fibrosis 10.5 IL10 TNF
21 clonorchiasis 10.4 IFNG IL10 TNF
22 orofacial granulomatosis 10.4 IFNG IL10 TNF
23 primary systemic mycosis 10.4 IFNG IL10 TNF
24 intermediate uveitis 10.4 IFNG IL10 TNF
25 eales disease 10.4 IFNG IL10 TNF
26 hemorrhagic fever 10.4 IFNG IL10 TNF
27 aseptic meningitis 10.4 IFNG IL10 TNF
28 chronic graft versus host disease 10.4 CD36 IFNG IL10
29 spotted fever 10.4 IFNG IL10 TNF
30 hematopoietic stem cell transplantation 10.4 IFNG IL10 TNF
31 mixed connective tissue disease 10.4 IFNG IL10 TNF
32 echinococcosis 10.4 IFNG IL10 TNF
33 transient hypogammaglobulinemia 10.4 IL10 TNF
34 reactive arthritis 10.4 IFNG IL10 TNF
35 leprosy 3 10.4 IFNG IL10 TNF
36 bronchiolitis obliterans 10.4 IFNG IL10 TNF
37 spondyloarthropathy 10.4 IFNG IL10 TNF
38 hemoglobinemia 10.4 HBB HP
39 pleural tuberculosis 10.4 IFNG IL18 TNF
40 gastroenteritis 10.4 IFNG IL10 TNF
41 primary progressive multiple sclerosis 10.4 ICAM1 IL10 TNF
42 osteomyelitis 10.4 IFNG IL10 TNF
43 rasmussen encephalitis 10.4 IFNG IL18 TNF
44 erythema multiforme 10.4 ICAM1 IFNG TNF
45 chlamydia 10.4 IFNG IL10 TNF
46 helicobacter pylori infection 10.4 IFNG IL10 TNF
47 toxic shock syndrome 10.4 IFNG IL10 TNF
48 pulmonary edema 10.4 ICAM1 IL10 TNF
49 pleurisy 10.4 ICAM1 IFNG TNF
50 graft-versus-host disease 10.4 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Plasmodium Falciparum Malaria:



Diseases related to Plasmodium Falciparum Malaria

Symptoms & Phenotypes for Plasmodium Falciparum Malaria

MGI Mouse Phenotypes related to Plasmodium Falciparum Malaria:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 FCGR2A G6PD IL10 HP CD36 ICAM1
2 cellular MP:0005384 10.27 IFNG G6PD HP CD36 ICAM1 DHFR
3 cardiovascular system MP:0005385 10.22 IFNG G6PD HP CD36 ICAM1 DHFR
4 homeostasis/metabolism MP:0005376 10.18 IFNG G6PD HP CD36 ICAM1 DHFR
5 immune system MP:0005387 10.17 IFNG FCGR2A HP CD36 ICAM1 CD55
6 digestive/alimentary MP:0005381 9.98 IFNG CD36 ICAM1 IL10 TLR9 IL18
7 mortality/aging MP:0010768 9.97 IFNG FCGR2A G6PD HP CD36 ICAM1
8 liver/biliary system MP:0005370 9.8 DHFR IFNG HP CD36 SELE IL10
9 muscle MP:0005369 9.56 DHFR IFNG CD36 ICAM1 IL10 IL18
10 neoplasm MP:0002006 9.1 IFNG HP ICAM1 MIF IL10 TNF

Drugs & Therapeutics for Plasmodium Falciparum Malaria

Drugs for Plasmodium Falciparum Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amodiaquine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 86-42-0 2165
2
Artemether Approved Phase 4,Phase 3,Phase 2,Phase 1 71963-77-4 68911 119380
3
Artesunate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 88495-63-0 5464098 6917864
4
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1 82186-77-4 6437380
5
Mefloquine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53230-10-7 4046
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
7
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54-05-7 2719
8
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 58-14-0 4993
9
Sulfadoxine Approved, Investigational Phase 4,Phase 2,Phase 3 2447-57-6 17134
10
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-34-6 4908
11
Nevirapine Approved Phase 4,Early Phase 1 129618-40-2 4463
12
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80-08-0 2955
13
Proguanil Approved Phase 4,Phase 2,Phase 3,Phase 1 500-92-5 4923
14
Quinine Approved Phase 4,Phase 3,Phase 2 130-95-0 3034034 8549
15
Atovaquone Approved Phase 4,Phase 2,Phase 3,Phase 1 95233-18-4 74989
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
18
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
19
Chlorproguanil Investigational Phase 4,Phase 3,Phase 2,Phase 1 537-21-3 9571037 151170
20 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1
22 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Artemether-lumefantrine combination Phase 4,Phase 3,Phase 2,Phase 1
25 Artemisinine Phase 4,Phase 3,Phase 2,Phase 1
26 Artemisinins Phase 4,Phase 3,Phase 2,Phase 1
27
Dihydroartemisinin Phase 4,Phase 3,Phase 2,Phase 1 71939-50-9 6918483
28
Piperaquine Phase 4,Phase 3,Phase 2,Phase 1 4085-31-8 5079497
29 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1
30 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Amodiaquine, artesunate drug combination Phase 4
32 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
33 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
34 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
36 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Chloroquine diphosphate Phase 4,Phase 3,Phase 2,Phase 1 50-63-5
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
41 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
42 Fanasil, pyrimethamine drug combination Phase 4,Phase 2,Phase 3
43 Renal Agents Phase 4,Phase 2,Phase 3
44 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Neuromuscular Agents Phase 4,Phase 3,Phase 2
46 Atovaquone, proguanil drug combination Phase 4,Phase 2,Phase 3,Phase 1
47 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
48 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
49 Red Cinchona Nutraceutical Phase 4,Phase 3,Phase 2
50
Azithromycin Approved Phase 2, Phase 3, Phase 1 83905-01-5 53477736 447043 55185

Interventional clinical trials:

(show top 50) (show all 310)

# Name Status NCT ID Phase Drugs
1 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
2 P. Falciparum Resistance to Artemisinin in Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
3 Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Unknown status NCT01930331 Phase 4 artemisinin/naphthoquine;dihydroartemisinin/piperaquine phosphate
4 Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
5 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
6 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
7 Assessment of Artesunate/Mefloquine in the Peruvian Amazon Unknown status NCT02084602 Phase 4 Artesunate;Mefloquine
8 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
9 Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania Unknown status NCT02199951 Phase 4 Dihydroartemisinin and piperaquine
10 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
11 Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia Completed NCT02325180 Phase 4 Dihydroartemisinin-Piperaquine;Artemether-lumefantrine
12 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Completed NCT02637128 Phase 4 artemether-lumefantrine (AL);artesunate-amodiaquine (ASAQ)
13 Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania Completed NCT03431714 Phase 4 Artesunate amodiaquine
14 Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. Completed NCT02089841 Phase 4 Artemether-lumefantrine
15 Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso Completed NCT01017770 Phase 4 Artesunate-amodiaquine;Artemether-lumefantrine
16 Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria Completed NCT00529867 Phase 4 Artemether/lumefantrine tablets;Artemether/Lumefantrine suspension
17 Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00540410 Phase 4 Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination);Coartem® (arthemether+ lumefantrine)
18 Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania Completed NCT00885287 Phase 4 Artemether-lumefantrine (AL)
19 Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00699920 Phase 4 Coarsucam;Coartem
20 Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria Completed NCT00978172 Phase 4 artesunate and mefloquine
21 Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan Completed NCT01019408 Phase 4 Chloroquine
22 Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger Completed NCT01755559 Phase 4 Artesunate-amodiaquine;Dihydroartemisinin-piperaquine;Artemether-lumefantrine
23 Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi Completed NCT00164359 Phase 4 Amodiaquine plus artesunate;chlorproguanil-dapsone plus artesunate
24 Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria Completed NCT00425763 Phase 4 AQAS
25 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
26 CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi Completed NCT00125489 Phase 4 chloroquine sulfate;sulfadoxine/pyrimethamine
27 Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo Completed NCT02940756 Phase 4 artesunate-amodiaquine;artemether-lumefantrine;Dihydroartemisinine-piperaquine
28 Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area Completed NCT00935688 Phase 4
29 Tracking Resistance to Artemisinin (TRAC) Completed NCT01350856 Phase 4 Artesunate 2;Artesunate 4
30 Kintampo Trial of Combination Therapy for Malaria Completed NCT00119145 Phase 4 artesunate-amodiaquine;coartem;artesunate-lapdap
31 Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru Completed NCT00164216 Phase 4 mefloquine plus artesunate
32 Harmonized AS/MQ Efficacy Study - Thailand Completed NCT02052323 Phase 4 Artesunate/mefloquine (AS/MQ)
33 Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers Completed NCT00233337 Phase 4 Co-artemether
34 Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine Completed NCT00167739 Phase 4 Quinine plus sulfadoxine-pyrimethamine
35 Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance Completed NCT00445796 Phase 4 Artesunate;Amodiaquine
36 Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire Completed NCT01023399 Phase 4 Artesunate + Amodiaquine
37 Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function Completed NCT00444106 Phase 4 Artesunate-mefloquine;Atovaquone-proguanil;Artemether-lumefantrine
38 A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects Completed NCT00859807 Phase 4 Flavoquine®, Camoquin® Suspension;Flavoquine®, Camoquin® Suspension
39 Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar Completed NCT00549003 Phase 4
40 Amodiaquine+Artesunate for Uncomplicated Malaria Treatment Completed NCT01213433 Phase 4 Artesunate-Amodiaquine
41 Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria Completed NCT02092766 Phase 4 artesunate;quinine
42 Plasmodium Falciparum Artemisinin Resistance Vietnam Completed NCT01775592 Phase 4 Arterakin (DHA-PPQ)
43 Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso Completed NCT01697787 Phase 4 Amodiaquine-Artesunate;Artemether-lumefantrine
44 Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo Completed NCT02741024 Phase 4 Amodiaquine-Artesunate (ASAQ);Artemether-Lumefantrine (AL)
45 In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children Completed NCT02168569 Phase 4 Coartem™ (Artemether-lumefantrine combination);Coarsucam™ (Amodiaquine-artesunate combination)
46 Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine Completed NCT01998295 Phase 4 Artemether/lumefantrine
47 Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy Completed NCT00495508 Phase 4 Quinine;artemether / lumefantrine
48 In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults Completed NCT00144352 Phase 4 sulfadoxine-pyrimethamine
49 ACT MALI: Treatment of Malaria Based on Combination Therapies Completed NCT00452907 Phase 4 Artesunate;Artesunate + Sulfadoxine-Pyrimethamine;arthemether + lumefantrine
50 In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy Completed NCT01976780 Phase 4 Artesunate;Artemether Lumefantrine;Mefloquine

Search NIH Clinical Center for Plasmodium Falciparum Malaria

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: malaria, falciparum

Genetic Tests for Plasmodium Falciparum Malaria

Anatomical Context for Plasmodium Falciparum Malaria

MalaCards organs/tissues related to Plasmodium Falciparum Malaria:

38
Testes, T Cells, Skin, Liver, Neutrophil, Endothelial, Monocytes

Publications for Plasmodium Falciparum Malaria

Articles related to Plasmodium Falciparum Malaria:

(show top 50) (show all 748)
# Title Authors Year
1
Posttreatment HRP2 Clearance in Patients with Uncomplicated Plasmodium falciparum Malaria. ( 29220497 )
2018
2
Blackwater fever in a non-immune patient with Plasmodium falciparum malaria after intravenous artesunate. ( 29394389 )
2018
3
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger. ( 29370844 )
2018
4
Treatment for Uncomplicated Plasmodium falciparum Malaria in French Soldiers Deployed in Sub-Saharan Africa: Gaps Between Policy and Field Practice. ( 29425320 )
2018
5
Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. ( 29347975 )
2018
6
Plasmodium falciparum malaria skews globin gene expression balance in in-vitro haematopoietic stem cell culture system: Its implications in malaria associated anemia. ( 29309785 )
2018
7
Multidrug-resistant Plasmodium falciparum malaria in the Greater Mekong subregion. ( 29398389 )
2018
8
Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial. ( 28605472 )
2017
9
Therapeutic plasma exchange in the treatment of complicated Plasmodium falciparum malaria: A case report. ( 28922459 )
2017
10
AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. ( 28916443 )
2017
11
Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum Malaria. ( 28722611 )
2017
12
Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa. ( 28785011 )
2017
13
Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis. ( 28028628 )
2017
14
Pulmonary manifestation of Plasmodium falciparum malaria: Case reports and review of the literature. ( 28702342 )
2017
15
Assessment of Myocardial Function and Injury by Echocardiography and Cardiac Biomarkers in African Children With Severe Plasmodium falciparum Malaria. ( 29206727 )
2017
16
Associations between an IgG3 polymorphism in the binding domain for FcRn, transplacental transfer of malaria-specific IgG3, and protection against Plasmodium falciparum malaria during infancy: A birth cohort study in Benin. ( 28991911 )
2017
17
Association of CD40L gene polymorphism with severe Plasmodium falciparum malaria in Indian population. ( 28352049 )
2017
18
Molecular surveillance of chloroquine drug resistance markers (Pfcrt and Pfmdr1) among imported Plasmodium falciparum malaria in Qatar. ( 29125042 )
2017
19
Obesity and Diabetes as Risk Factors for Severe Plasmodium falciparum Malaria: Results From a Swedish Nationwide Study. ( 28510633 )
2017
20
Individual and household characteristics of persons with Plasmodium falciparum malaria in sites with varying endemicities in Kinshasa Province, Democratic Republic of the Congo. ( 29121931 )
2017
21
Analysis of the Clinical Profile in Patients with Plasmodium falciparum Malaria and Its Association with Parasite Density. ( 28584457 )
2017
22
A Case of Severe Plasmodium falciparum Malaria Co-Infected with HIV Improved with Exchange Transfusion. ( 29318993 )
2017
23
Age and geographic patterns of Plasmodium falciparum malaria infection in a representative sample of children living in Burkitt lymphoma-endemic areas of northern Uganda. ( 28320389 )
2017
24
Severe Plasmodium falciparum malaria in the intensive care unit: A 6-year experience in Milano, Italy. ( 28554853 )
2017
25
K13-propeller Alleles, Mdr1 Polymorphism, and Drug Effectiveness at Day 3 after Artemether-lumefantrine Treatment for Plasmodium falciparum Malaria in Colombia, 2014-2015. ( 28947476 )
2017
26
Plasmodium falciparum malaria co-infection with tick-borne relapsing fever in Dakar. ( 28077149 )
2017
27
Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. ( 28454557 )
2017
28
High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series. ( 27986683 )
2017
29
Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis. ( 29137664 )
2017
30
Comparative study of clinical presentation and hematological indices in hospitalized sickle cell patients with severe Plasmodium falciparum malaria. ( 28927555 )
2017
31
The oxylipin and endocannabidome responses in acute phase Plasmodium falciparum malaria in children. ( 28886714 )
2017
32
Elimination of Plasmodium falciparum malaria in Tajikistan. ( 28558764 )
2017
33
Expression of cleaved caspase-3 in renal tubular cells in Plasmodium falciparum malaria patients. ( 26729581 )
2017
34
To prevent or ameliorate severe Plasmodium falciparum malaria, why not evaluate the impact of exchange transfusions of sickle cell trait red blood cells? ( 29310873 )
2017
35
Multicenter Pivotal Clinical Trial of Urine Malaria Test for Rapid Diagnosis of Plasmodium falciparum Malaria. ( 27847373 )
2017
36
Effects of Aging on Parasite Biomass, Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in Plasmodium knowlesi and Plasmodium falciparum Malaria. ( 28863470 )
2017
37
Sustained High Cure Rate of Artemether-Lumefantrine against Uncomplicated Plasmodium falciparum Malaria after 8 Years of Its Wide-Scale Use in Bagamoyo District, Tanzania. ( 28829723 )
2017
38
Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria. ( 29244851 )
2017
39
Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in CA'te d'Ivoire. ( 28049523 )
2017
40
Plasmodium falciparum malaria parasite var gene expression is modified by host antibodies: longitudinal evidence from controlled infections of Kenyan adults with varying natural exposure. ( 28835215 )
2017
41
Congenital Plasmodium falciparum Malaria in Washington, DC. ( 28077745 )
2017
42
Evidence of non-Plasmodium falciparum malaria infection in KAcdougou, SAcnAcgal. ( 28049489 )
2017
43
Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. ( 28566213 )
2017
44
Combating multidrug-resistant Plasmodium falciparum malaria. ( 28580606 )
2017
45
Performance of a High-Sensitivity Rapid Diagnostic Test for Plasmodium falciparum Malaria in Asymptomatic Individuals from Uganda and Myanmar and Naive Human Challenge Infections. ( 28820709 )
2017
46
TRALI Syndrome During the Treatment of a Plasmodium falciparum Malaria Case. ( 28091389 )
2016
47
Artemisinin-Resistant Plasmodium falciparum Malaria. ( 27337450 )
2016
48
Quantitative, model-based estimates of variability in the generation and serial intervals of Plasmodium falciparum malaria. ( 27660051 )
2016
49
Spatial and space-time distribution of Plasmodium vivax and Plasmodium falciparum malaria in China, 2005-2014. ( 27993171 )
2016
50
The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria. ( 27604417 )
2016

Variations for Plasmodium Falciparum Malaria

Expression for Plasmodium Falciparum Malaria

Search GEO for disease gene expression data for Plasmodium Falciparum Malaria.

Pathways for Plasmodium Falciparum Malaria

Pathways related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 CD36 CD55 CHIT1 CR1 FCGR2A HBB
2
Show member pathways
12.78 CD55 ICAM1 IFNG IL10 TNF
3
Show member pathways
12.73 ICAM1 IFNG IL18 TLR9 TNF
4
Show member pathways
12.29 DHFR HBB ICAM1 IFNG TNF
5
Show member pathways
12.18 CR1 FCGR2A IFNG IL10 TNF
6
Show member pathways
12.12 IFNG IL10 IL18 TNF
7 12.06 ICAM1 IFNG SELE TNF
8 12.05 CR1 FCGR2A IFNG IL10 IL18 TLR9
9 11.95 FCGR2A ICAM1 IFNG MIF TNF
10 11.92 CD36 FCGR2A IFNG IL10 TNF
11 11.89 CD36 ICAM1 IL10 IL18 TNF
12
Show member pathways
11.86 CD36 HBB HP
13 11.86 CD36 CD55 CR1 TNF
14 11.83 ICAM1 SELE TNF
15 11.82 IFNG IL10 TNF
16 11.82 ICAM1 IFNG IL18 TNF
17
Show member pathways
11.78 IFNG IL10 IL18 TLR9 TNF
18 11.76 CR1 FCGR2A TLR9
19 11.75 IFNG IL10 IL18 TNF
20 11.74 ICAM1 IFNG SELE
21 11.71 IFNG IL10 TLR9 TNF
22 11.56 FCGR2A ICAM1 IL10
23 11.55 CR1 IL18 TNF
24
Show member pathways
11.52 ICAM1 IFNG MIF SELE TNF
25 11.52 CD36 CR1 FCGR2A ICAM1 IL10 TLR9
26 11.49 HP ICAM1 TNF
27 11.49 ICAM1 IL10 IL18 TNF
28 11.48 IFNG IL18 TNF
29
Show member pathways
11.34 IFNG IL10 TNF
30 11.34 CD36 CR1 HBB ICAM1 IFNG IL10
31 11.28 IFNG IL18 TNF
32 11.24 IFNG IL10 TNF
33 11.16 ICAM1 IFNG IL18
34 10.9 CD36 ICAM1 TNF
35 10.77 HBB ICAM1 IFNG IL10 IL18 SELE

GO Terms for Plasmodium Falciparum Malaria

Cellular components related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CD55 CHIT1 HBB HP IFNG IL10
2 cell surface GO:0009986 9.73 CD36 CD55 CR1 ICAM1 MIF TNF
3 secretory granule membrane GO:0030667 9.61 CD55 CR1 FCGR2A
4 tertiary granule lumen GO:1904724 9.54 CHIT1 HBB HP
5 endocytic vesicle lumen GO:0071682 9.46 HBB HP
6 extracellular space GO:0005615 9.4 CD36 CHIT1 HBB HP ICAM1 IFNG
7 membrane raft GO:0045121 9.35 CD36 CD55 ICAM1 SELE TNF
8 haptoglobin-hemoglobin complex GO:0031838 9.32 HBB HP
9 extracellular exosome GO:0070062 10.1 CD55 CR1 FCGR2A G6PD HBB HP

Biological processes related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.98 CD36 IFNG IL18 TLR9 TNF
2 negative regulation of gene expression GO:0010629 9.96 CD36 IFNG MIF TNF
3 leukocyte migration GO:0050900 9.96 ICAM1 MIF SELE TNF
4 defense response to bacterium GO:0042742 9.95 HP IL10 TLR9 TNF
5 immune response GO:0006955 9.95 CD36 CHIT1 IFNG IL10 IL18 TNF
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.94 CD36 ICAM1 MIF TNF
7 viral entry into host cell GO:0046718 9.85 CD55 CR1 ICAM1
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 CD36 ICAM1 TLR9 TNF
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 CD36 ICAM1 MIF
10 cellular response to lipopolysaccharide GO:0071222 9.81 CD36 ICAM1 IL10 TNF
11 interleukin-12-mediated signaling pathway GO:0035722 9.8 IFNG IL10 MIF
12 response to hydrogen peroxide GO:0042542 9.8 HBB HP MB
13 positive regulation of cell death GO:0010942 9.75 CD36 HBB HP
14 positive regulation of tumor necrosis factor production GO:0032760 9.74 CD36 MIF TLR9
15 positive regulation of interleukin-6 production GO:0032755 9.73 CD36 TLR9 TNF
16 inflammatory response GO:0006954 9.73 IL10 IL18 MIF SELE TLR9 TNF
17 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.69 CD36 IL18
18 leukocyte tethering or rolling GO:0050901 9.69 SELE TNF
19 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.68 IFNG TNF
20 oxygen transport GO:0015671 9.68 HBB MB
21 regulation of regulatory T cell differentiation GO:0045589 9.68 CR1 IFNG
22 response to molecule of bacterial origin GO:0002237 9.68 IL10 TLR9
23 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 TNF
24 positive regulation of cytokine secretion GO:0050715 9.67 IL10 MIF TNF
25 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.66 IL18 TLR9
26 endothelial cell apoptotic process GO:0072577 9.65 IL10 TNF
27 regulation of removal of superoxide radicals GO:2000121 9.63 CD36 DHFR
28 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.62 ICAM1 TNF
29 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 IL10 TNF
30 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.61 MIF TNF
31 type 2 immune response GO:0042092 9.6 IL10 IL18
32 negative regulation of interleukin-8 production GO:0032717 9.59 IL10 TLR9
33 negative regulation of interleukin-6 production GO:0032715 9.58 IL10 TLR9 TNF
34 neutrophil degranulation GO:0043312 9.56 CD36 CD55 CHIT1 CR1 FCGR2A HBB
35 receptor biosynthetic process GO:0032800 9.54 IL10 TNF
36 positive regulation of interleukin-12 production GO:0032735 9.54 CD36 IFNG TLR9
37 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 IFNG TNF
38 positive regulation of NF-kappaB import into nucleus GO:0042346 9.5 IL18 TLR9 TNF
39 positive regulation of vitamin D biosynthetic process GO:0060557 9.46 IFNG TNF
40 positive regulation of blood microparticle formation GO:2000334 9.43 CD36 TNF
41 negative regulation of growth of symbiont in host GO:0044130 9.33 CD36 IL10 TNF
42 positive regulation of nitric oxide biosynthetic process GO:0045429 9.02 CD36 HBB ICAM1 IFNG TNF
43 regulation of receptor activity GO:0010469 10.04 IFNG IL10 IL18 MIF TNF

Molecular functions related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.33 CD55 CR1 ICAM1
2 oxygen carrier activity GO:0005344 9.26 HBB MB
3 cytokine activity GO:0005125 9.02 IFNG IL10 IL18 MIF TNF
4 hemoglobin binding GO:0030492 8.96 HBB HP

Sources for Plasmodium Falciparum Malaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....